STOCK TITAN

Actinium Pharmaceuticals Provides Third Quarter 2026 Corporate Update Highlighting ATNM-400 and Other Business Progress

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Actinium Pharmaceuticals (ATNM) reported initial Phase 1/2a results for its HER3-targeted ATNM-400 radiotherapy in metastatic castration-resistant prostate cancer.

The first cohort cleared 1.0 µCi/kg without dose-limiting toxicities; imaging showed tumor uptake retained through Day 7. Dose escalation to 1.5 µCi/kg is ongoing. The first patient was dosed in RADIANZ, an imaging study evaluating HER3 across five other cancer types. Preclinical studies also showed activity in lung, colorectal and ovarian cancer models.

Cash and cash equivalents totaled $28.7 million at September 30, 2026, which Actinium expects to fund operations through 2027. The company is establishing in-house manufacturing and expects it to be operational around year-end.

Loading...
Loading translation...
8 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.$28.7 million cash and cash equivalents at September 30, 2026; Actinium expects funding through 2027.
  • Minor pointATNM-400 first cohort cleared 1.0 µCi/kg without dose-limiting toxicities in the Phase 1/2a prostate cancer study.
  • Minor pointATNM-400 imaging showed tumor uptake retained through Day 7.
  • Minor pointDose escalation advanced to 1.5 µCi/kg and remains ongoing.
  • Minor pointRADIANZ first patient dosed in HER3 imaging study covering lung, breast, colorectal, pancreatic and ovarian cancers.
3 minor points
  • Minor pointPreclinical ATNM-400 data demonstrated antitumor activity in non-small cell lung, colorectal and ovarian cancer models.
  • Minor point. Forward-looking: it has not happened yet and may not happen.In-house manufacturing is being established; Actinium expects operations to begin around year-end.
  • Minor point. Forward-looking: it has not happened yet and may not happen.2027 milestones anticipated by Actinium include clinical data and development progress across ATNM-400, Actimab-A and Iomab-ACT.

Negative

  • None.

Key Figures

Dose level cleared: 1.0 µCi/kg Tumor uptake: Through Day 7 Dose escalation: 1.5 µCi/kg +1 more
Dose level cleared
1.0 µCi/kg
First cohort; no dose-limiting toxicities
Tumor uptake
Through Day 7
Imaging in the first-in-human HERACT-PRO-1 study
Dose escalation
1.5 µCi/kg
Ongoing in HERACT-PRO-1
Cash and cash equivalents
$28.7 million
As of September 30, 2026; expected to fund operations through 2027

Key Terms

her3, mcrpc, dose-limiting toxicities, pet imaging
4 terms
her3 medical
"HER3 as the target of ATNM-400"
HER3 is a protein on the surface of cells that acts like an antenna or switch to receive growth signals; when it malfunctions or is hijacked it can help cancers grow. Investors care because therapies or diagnostics that block or measure HER3 can change a drug candidate’s commercial prospects, clinical trial value and regulatory odds, making related biotech and pharmaceutical firms more or less valuable.
mcrpc medical
"metastatic castration-resistant prostate cancer (mCRPC)"
mCRPC stands for metastatic castration‑resistant prostate cancer, a form of prostate cancer that has spread beyond the prostate and keeps progressing despite treatments that lower male hormones. It matters to investors because this stage is harder to treat, drives demand for new therapies, and often involves large, expensive clinical trials and regulatory decisions that can strongly influence a drug maker’s future revenue and stock value—think of it as a stubborn problem that creates both medical need and commercial opportunity.
dose-limiting toxicities medical
"with no dose-limiting toxicities"
Dose-limiting toxicities are the harmful side effects seen in early clinical trials that are severe enough to stop researchers from raising a drug’s dose. Like a car’s speed limiter marking the safe top speed, DLTs define the maximum tolerable dose, and they matter to investors because they determine whether a medicine can reach effective levels, influence development timelines, costs, and regulatory chances, and thus affect a drug’s commercial prospects.
pet imaging medical
"a HER3 PET imaging study"
PET imaging is a noninvasive medical scan that works like a molecular camera, using tiny radioactive tracers to reveal biological activity inside the body—for example metabolism, blood flow, or the presence of specific proteins. It matters to investors because PET results guide diagnosis, show whether a drug reaches its intended target and how patients respond, and therefore affect clinical trial success, regulatory approval, reimbursement decisions and demand for scanners, tracers and related services.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • Announced HER3 as the target of ATNM-400 and presented initial data from the first-in- human HERACT-PRO-1 Phase 1/2a study in metastatic castration-resistant prostate cancer (mCRPC) at EANM 2026
  • Initiated RADIANZ pan-tumor imaging study to inform ATNM-400 development across multiple solid tumors beyond prostate cancer
  • Formed Scientific Advisory Board and strengthened leadership team to support strategic execution, business development and continued pipeline advancement
  • KOL webinar on ATNM-400 on December 1, 2026, at 8:00 a.m. ET with Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center

NEW YORK, Nov. 17, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies with the potential to transform cancer treatment, today provided a third quarter 2026 corporate update highlighting recent clinical progress with ATNM-400, initiation of its RADIANZ pan-tumor imaging study, and advancements across its broader pipeline. With ATNM-400 now in clinical development for prostate cancer and multiple clinical and scientific milestones anticipated across its portfolio in 2027, Actinium is entering an important period of pipeline advancement.

Actinium Pharmaceuticals Logo

"With ATNM-400 now in the clinic, we are advancing a differentiated HER3-targeted approach to alpha radiotherapy with the potential to address significant unmet needs in prostate cancer beyond PSMA," said Sandesh Seth, Actinium's Chairman and Chief Executive Officer. "Our encouraging initial clinical findings support continued dose escalation in mCRPC, while RADIANZ represents an important next step in evaluating HER3 targeting across multiple large solid tumor indications. Looking ahead, 2027 is shaping up to be an important year for Actinium, with anticipated clinical data and development milestones across ATNM-400, Actimab-A and Iomab-ACT. Together with our newly formed Scientific Advisory Board and strengthened leadership team, we believe we are well positioned to execute on these priorities and build value across our differentiated targeted radiotherapy pipeline."

Third Quarter 2026 and Recent Highlights

ATNM-400: First-in-Class HER3-Targeted Alpha Radiotherapy

  • Target disclosed and encouraging first-in-human data presented at EANM 2026. Actinium announced HER3, an antigen distinct from PSMA and implicated in treatment resistance, as the target of ATNM-400 and presented initial results from the ongoing HERACT-PRO-1 Phase 1/2a study in mCRPC. The first cohort cleared the 1.0 µCi/kg dose level with no dose-limiting toxicities, and imaging showed tumor uptake retained through Day 7. Dose escalation has advanced to 1.5 µCi/kg and is ongoing. The study was also featured at ESMO 2026.
  • RADIANZ pan-tumor imaging study enrolling to inform development beyond prostate cancer. The first patient was dosed in RADIANZ, a HER3 PET imaging study in advanced lung, breast, colorectal, pancreatic and ovarian cancers designed to inform ATNM-400 development beyond prostate cancer.
  • Preclinical data reinforce ATNM-400's pan-tumor potential. New data presented at EANM demonstrated antitumor activity across non-small cell lung cancer (NSCLC), colorectal and ovarian cancer models, supporting the potential of ATNM-400 as a monotherapy and in combination with established treatments. Additional preclinical findings highlighting activity across breast cancer models will be presented at SABCS 2026.

Hematology Programs

  • Four abstracts accepted for presentation at ASH 2026: Presentations will highlight long-term safety findings for Actimab-A plus CLAG-M in relapsed or refractory AML, as well as Iomab-ACT's potential as a targeted conditioning agent for CAR T-cell and gene therapies.

Corporate

  • Formed Scientific Advisory Board of leading experts in prostate cancer, hematologic malignancies, radiochemistry and nuclear medicine: Karim Fizazi, MD, PhD (Centre Oscar Lambret and Paris-Saclay University); Sergio A. Giralt, MD (Memorial Sloan Kettering Cancer Center); Jason S. Lewis, PhD (Memorial Sloan Kettering Cancer Center); Michael J. Morris, MD (Memorial Sloan Kettering Cancer Center); and Neeta Pandit-Taskar, MD, MBA (University of Pittsburgh Medical Center).
  • Strengthened leadership team with key appointments. Appointed Matt David, M.D., as Chief Financial Officer, bringing more than 20 years of public company finance, capital markets and investment banking experience, most recently at CorMedix, and Sean Maenpaa as Senior Vice President, Business Development, a radiopharmaceutical business development veteran from Bayer, Clovis Oncology and Telix Pharmaceuticals.
  • Financial position: Cash and cash equivalents of $28.7 million as of September 30, 2026 are expected to fund operations through 2027.

Upcoming Events

  • December 1 – KOL Webinar on ATNM-400: Actinium will host a webinar at 8:00 a.m. ET featuring Michael J. Morris, MD, Prostate Cancer Section Head at Memorial Sloan Kettering Cancer Center. The discussion will focus on unmet needs in mCRPC, the potential for HER3-targeted alpha radiotherapy beyond PSMA, and management's review of previously reported HERACT-PRO-1 clinical findings and the RADIANZ imaging study.   Register here.
  • December 8-11 – SABCS 2026: Actinium will present preclinical data demonstrating ATNM-400's activity across therapy-resistant breast cancer models, further supporting its potential across multiple solid tumor indications. The poster presentation is scheduled for December 9, 2026.
  • December 12-15 – ASH 2026: Actinium will present clinical findings from its Actimab-A and Iomab-ACT programs, highlighting continued development in AML, CAR T-cell conditioning and gene therapy conditioning.

Looking ahead, Actinium expects a steady cadence of clinical data, scientific presentations and development milestones throughout 2027 as it advances ATNM-400 in prostate cancer and evaluates its broader solid tumor potential, alongside continued progress across its hematology pipeline. In addition, Actinium continues to establish in-house manufacturing capabilities to support its clinical programs and expects to be operational by around year-end.

About Actinium Pharmaceuticals, Inc.

Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The Company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its pipeline spans three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. Actinium also holds approximately 250 patents and patent applications, including intellectual property related to cyclotron-based production of Actinium-225. For more information, please visit www.actiniumpharma.com.

About ATNM-400

ATNM-400 is an investigational antibody radioconjugate that pairs the HER3-targeting monoclonal antibody barecetamab with the alpha-emitting isotope Actinium-225. Its antibody-based design combines antigen-specific targeting with the potential for sustained tumor localization, supporting prolonged delivery of high-energy alpha radiation. Tumor uptake and retention observed through Day 7 with the ⁸⁹Zr-labeled imaging counterpart support this development rationale alongside the approximately 10-day half-life of ²²⁵Ac. The theranostic approach enables noninvasive visualization of antibody distribution to inform therapeutic development.  The program is being evaluated in a first-in-human dose-escalation Phase 1/2a study of ATNM-400 in mCRPC, HERACT-PRO-1, which utlizes Zirconium-89-labeled barecetamab PET imaging to assess tumor targeting, biodistribution and dosimetry. Actinium is also conducting an imaging study, RADIANZ (Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89) using PET to guide the pan-tumor development of ATNM-400 in various solid tumors outside of prostate cancer.

ATNM-400 is differentiated from PSMA-targeted radiotherapies by its focus on HER3, an antigen implicated in tumor survival and treatment resistance. PSMA-directed approaches include Novartis' Pluvicto and a broad pipeline of investigational therapies, including Telix Pharmaceuticals' TLX591-Tx, Clarity Pharmaceuticals' ⁶⁷Cu-SAR-bisPSMA, Convergent Therapeutics' CONV01-α, AstraZeneca's AZD2265 (formerly FPI-2265), Curium's lutetium-177 zadavotide guraxetan (¹⁷⁷Lu-PSMA-I&T), ARTBIO's AB001 and AdvanCell's ADVC001. These programs span small-molecule and antibody-based therapies using beta- or alpha-emitting isotopes. ATNM-400 combines HER3 targeting with an Actinium-225 antibody radioconjugate, offering a distinct biological approach with the potential to expand radiotherapy across the broad mCRPC population, including patients with PSMA-low or PSMA-negative disease and those who do not respond to or progress following PSMA-directed treatment. Its HER3-directed mechanism also supports investigation beyond prostate cancer in other HER3-expressing solid tumors.

About HER3

HER3, also known as ERBB3, belongs to the epidermal growth factor receptor family and participates in signaling pathways that promote tumor growth, survival and treatment resistance. HER3-directed antibody-drug conjugates (ADCs) in clinical development include BioNTech and MediLink's BNT326/YL202; Bristol Myers Squibb and SystImmune's EGFR × HER3 bispecific ADC, izalontamab brengitecan (iza-bren); and Daiichi Sankyo and Merck's patritumab deruxtecan (HER3-DXd). These programs highlight clinical development interest in HER3 as an oncology target. ATNM-400 takes a different payload approach, delivering alpha radiation rather than a conventional cytotoxic drug. Preclinical activity in prostate, non-small cell lung, breast, colorectal and ovarian cancer models supports investigating ATNM-400 as a potential pan-cancer radiotherapy, both as monotherapy and in rational combinations.

Forward-Looking Statements

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995 regarding future events or future financial performance of the Company, which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from anticipated or estimated future results, including risks and uncertainties associated with the conduct, timing and results of the ongoing first-in-human HERACT-PRO-1 Phase 1/2a study of ATNM-400 and the RADIANZ imaging study, including the possibility that preliminary results may differ from final results and that preclinical results may not be predictive of clinical outcomes; the sufficiency of the Company's cash resources to fund its planned operations; the potential of product candidates; clinical trials; actions by the FDA and other governmental agencies; regulatory clearances; market demand for and acceptance of the Company's products and services; performance of clinical research organizations; and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, each as amended and supplemented from time to time.

Investors Contact:
Peter (PJ) Kelleher
LifeSci Advisors
pkelleher@lifesciadvisors.com
(617) 430-7579

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-provides-third-quarter-2026-corporate-update-highlighting-atnm-400-and-other-business-progress-302941318.html

SOURCE Actinium Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Actinium's ATNM-400 Phase 1/2a prostate cancer study show?

The first cohort cleared 1.0 µCi/kg without dose-limiting toxicities, and imaging showed tumor uptake retained through Day 7. Dose escalation has advanced to 1.5 µCi/kg and is ongoing in the HERACT-PRO-1 study of metastatic castration-resistant prostate cancer.

How long does Actinium expect its cash to fund operations?

Actinium expects its $28.7 million in cash and cash equivalents as of September 30, 2026, to fund operations through 2027.

What will Actinium present at SABCS and ASH 2026?

Actinium will present preclinical ATNM-400 findings in therapy-resistant breast cancer models at SABCS on December 9, 2026. Four abstracts accepted for ASH will highlight long-term safety findings for Actimab-A plus CLAG-M in relapsed or refractory acute myeloid leukemia and Iomab-ACT's potential for conditioning patients before CAR T-cell and gene therapies.

Keep reading